r The conditional knockout of MYPT1 or the knock-in mutation T853A in mice had no effect on muscarinic force responses in isolated tracheal tissues. MLCP activity may arise from functionally shared roles between MYPT1 and MBS85, resulting in minimal effects of MYPT1 knockout on contraction.
r The conditional knockout of MYPT1 or the knock-in mutation T853A in mice had no effect on muscarinic force responses in isolated tracheal tissues. MLCP activity may arise from functionally shared roles between MYPT1 and MBS85, resulting in minimal effects of MYPT1 knockout on contraction.
Introduction
G protein-coupled receptor signalling pathways, as well as voltage-dependent Ca 2+ influx or release from the sarcoplasmic reticulum, increase smooth muscle cell [Ca 2+ ] i to activate Ca 2+ /calmodulin-dependent myosin light chain kinase (MLCK) for myosin regulatory light chain (RLC) phosphorylation and force production (Kamm & Stull, 1985a; Hartshorne, 1987; Trybus, 1994; Wendt et al. 1999; Somlyo & Somlyo, 2003; Lowey & Trybus, 2010) . Dedicated MLCK is the only kinase phosphorylating RLC physiologically in different kinds of smooth muscles (He et al. 2008; Zhang et al. 2010; He et al. 2011; Gao et al. 2013; Gao et al. 2016) . The activation of MLCK is also modulated by a phosphorylation that diminishes its activity, thereby fine tuning the RLC phosphorylation response (Stull et al. 1990; Kamm & Stull, 2001; Tsai et al. 2012; Gao et al. 2016) .
Myosin light chain phosphatase (MLCP) dephosphorylates RLC, and induces relaxation after a decrease in [Ca 2+ ] i returns MLCK to an inactive state (Hartshorne, 1987; Somlyo & Somlyo, 2003; Hartshorne et al. 2004; Grassie et al. 2011) . MLCP is a holoenzyme composed of three distinct subunits: a 38 kDa catalytic subunit (PP1cδ), a large 110-130 kDa regulatory subunit (MYPT1) and a small 20 kDa subunit of unknown function (Matsumura & Hartshorne, 2008; Grassie et al. 2011) . Biochemically, MYPT1 binds PP1cδ and myosin and thus functions as a scaffolding protein. However, we recently reported that another MYPT family member (Grassie et al. 2011) , myosin binding subunit 85 (MBS85), was expressed in smooth muscles and may also tether PP1cδ to myosin filaments as a scaffolding protein. (Tsai et al. 2014; Gao et al. 2016) . MBS85 is shorter than MYPT1 but contains the RVxF motif and a more N-terminal site with the consensus sequence RxxQV/I/LK/RxY/W that, similar to MYPT1, probably serves as a scaffolding protein that binds both PP1cδ and myosin (Terrak et al. 2004; Grassie et al. 2011) .
Different signalling pathways are proposed to inhibit MLCP activity, thereby increasing RLC phosphorylation without changing elevated [Ca 2+ ] i (Ca 2+ sensitization). Ca 2+ sensitization in intact smooth muscle tissues may be mediated, in part, by phosphorylation of a small inhibitor protein CPI-17 (PKC-potentiated protein phosphatase 1 inhibitor protein of 17 kDa) at T38 by protein kinase C (Sakai et al. 2005; Eto, 2009; Mukherjee et al. 2013; Eto & Kitazawa, 2017) . MYPT1 phosphorylation may also mediate Ca 2+ sensitization responses. High constitutive phosphorylation of MYPT1 at T696 is found in different kinds of resting smooth muscles and is not increased extensively in response to agonists, particularly in vascular smooth muscles (Kitazawa et al. 2003; Niiro et al. 2003; Wilson et al. 2005; Khromov et al. 2009; Ratz & Miner, 2009; Alvarez et al. 2010; Tsai et al. 2014; Eto & Kitazawa, 2017) . MBS85 contains T560 analogous to MYPT1 696 but does not have the C-terminal sequence containing a site such as MYPT1 T853 that could be phosphorylated.
Agonist-mediated Ca 2+ sensitization has been proposed to involve phosphorylation of MYPT1 T853 by Rho kinase (ROCK) (Somlyo & Somlyo, 2003; Hartshorne et al. 2004; Dimopoulos et al. 2007; Matsumura & Hartshorne, 2008; Kitazawa, 2010; Grassie et al. 2011; Brozovich et al. 2016) . Although MYPT1 T853 phosphorylation is significantly increased in response to agonist treatment in many kinds of smooth muscles, recent studies with a mammalian cellular reconstitution of MLCP subunits show the effect of MYPT1 T853 phosphorylation on MLCP activity to be negligible (Khasnis et al. 2014) , confirming an earlier biochemical study (Feng et al. 1999) . Additionally, a knock-in mutation of nonphosphorylatable MYPT1 T853A did not change agonist-induced RLC phosphorylation and force development in two phasic smooth muscles: the urinary bladder (Chen et al. 2015) and ileum . Studies in a tonic smooth muscle have not been reported.
Recent studies have also found there are differences between pharmacological vs. neurotransmitter activation of G protein-coupled receptors in terms of MYPT1 phosphorylation responses. In isolated urinary bladder tissues, electric field stimulation (EFS) causing release of ACh from parasympathetic nerves resulted in increases in [Ca 2+ ] i , Ca 2+ /calmodulin activation of MLCK, as well as RLC phosphorylation within 100 ms with maximal responses obtained by 1 s without MYPT1 phosphorylation (Ding et al. 2009 ). Prolonged neurostimulation for up to 10 s did not result in MYPT1 phosphorylation, although CPI-17 was phosphorylated (Tsai et al. 2012) . Cholinergic neurostimulation of gastric fundus smooth muscle also did not result in MYPT1 phosphorylation, whereas RLC and CPI-17 were phosphorylated (Bhetwal et al. 2013) . Pre-treatment with the cholinesterase inhibitor neostigmine resulted in the additional MYPT1 phosphorylation, which is similar to the response obtained with an agonist. Evidence was presented to suggest that intramuscular interstitial cells of Cajal (ICC-IM) may limit access of ACh to gastric smooth muscle cells with neurostimulation so that Ca 2+ sensitization mechanisms involving MYPT1 phosphorylation are not activated. Similar responses were obtained in ileal smooth muscle .
The role of MYPT1 as an essential regulator of MLCP activity has been recently re-examined. After the conditional knockout of MYPT1 in smooth muscles of adult mice, the mesenteric artery (Qiao et al. 2014) , bladder (Tsai et al. 2014) and ileal Gao et al. 2016 ) strips developed force with RLC phosphorylation and relaxed with RLC dephosphorylation in response to KCl and agonist treatments. Although MBS85 was expressed in bladder and ileal smooth muscle in smaller amounts compared to MYPT1, it may share functional targeting of PP1cδ to myosin filaments and thus reduce effects of MYPT1 deficiency (Tsai et al. 2014; Gao et al. 2016) . PP1cδ specific activity in supernatant fractions of smooth muscle homogenates not containing myosin, MYPT1 or MBS85 suggested an additional soluble phosphatase activity that may dephosphorylate RLC physiologically (Tsai et al. 2014) .
In the present study, we investigated the pharmacological responses of muscarinic G protein-coupled receptor activation by carbachol in relation to signalling to RLC phosphorylation and force development in the tonic tracheal smooth muscle. Because airway smooth muscle does not contain ICC-IM similar to gastrointestinal tissues, we compared bath applied agonist responses to cholinergic neurotransmission responses elicited by EFS. We then extended these investigations with genetically modified mice to address important questions regarding the potential regulation of RLC phosphorylation by MYPT1 and MYPT1 T853 phosphorylation. The results from these studies led to the following conclusions: (i) MYPT1 T853 is phosphorylated pharmacologically but not with neurostimulation of tracheal smooth muscle; (ii) MYPT1 T853 phosphorylation does not affect MLCP activity; and (iii) unlike MLCK, MYPT1 is not necessary for tonic airway smooth muscle contraction and relaxation. MYPT1 may functionally share a role in RLC dephosphorylation with MBS85.
Methods

Ethical approval
Experiments were performed in accordance with the National Institutes of Health and Institutional Animal Care and Use Guidelines. The Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Centre approved all procedures and protocols in compliance with principles and standards for reporting animal experiments in The Journal of Physiology (Grundy, 2015) . Animals were killed by the I.P. administration of a lethal dose of tribromoethanol (250 mg kg −1 ) for tissue collection.
Generation of genetically modified mice
Mice containing floxed Mypt1 alleles (Mypt1 f/f ) were crossed with a transgenic mouse line expressing a fusion protein of the Cre recombinase with the modified oestrogen receptor binding domain (CreER T2 ) under the control of the smooth muscle myosin heavy chain (SMMHC) promoter (Wirth et al. 2008) . Cre-mediated recombination occurred robustly and exclusively in smooth muscle cells in tissues, although only after tamoxifen treatment (Wirth et al. 2008) . Mice were bred and screened as described previously (Wirth et al. 2008; He et al. 2013; Tsai et al. 2014) . Male mice (8-10 weeks old) were injected I.P. with tamoxifen or vehicle for five consecutive days each week for 2 weeks at a dose of 1 mg day −1 (Tsai et al. 2014) . Trachea tissues were harvested 6-7 weeks after starting tamoxifen treatment from transgenic mice containing Mypt1 f/f, Cre+ alleles (denoted as MYPT1 SM-/− mice) and age-matched vehicle-treated male littermate mice (denoted as MYPT1 SM+/+ mice). Mice containing the MYPT1 T852A mutation (numbering based on mouse MYPT1 sequence) with alanine replacing threonine 852 (Chen et al. 2015) were also used for experiments on isolated trachea. To be consistent with previous published biochemical investigations on the phosphorylation properties of MYPT1 phosphorylation by ROCK (Somlyo & Somlyo, 2003; Hartshorne et al. 2004; Grassie et al. 2011) , this mutation is referred to as MYPT1 T853A with the human isoform numbering sequence, which is also used for MYPT1 T696 and T853 phosphorylation sites.
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Measurements of bovine and mouse trachea smooth muscle contraction Bovine tracheas were obtained from a local abattoir (Dallas City Packing, Dallas, TX, USA) and transported to the laboratory on ice for immediate immersion in cool physiological salt solution (PSS) (in mM): 118.5 NaCl, 4.75 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 24.9 NaHCO 3 , 1.6 CaCl 2 and 10.0 D-glucose, aerated with 95% O 2 -5% CO 2 to maintain pH at 7.4). Tracheal smooth muscle tissue was carefully dissected free from the tunica mucosa and adventitia. Strips of uniform dimensions (1.8 mm 2) were cut parallel to the long axis of the cells with a double-blade cutting tool. Tissue had an average wet weight of 7 mg with 95% smooth muscle cells (Kamm & Stull, 1985b) . After death, tracheal rings of mice were isolated and connective tissue removed for force measurements as described previously (Zhang et al. 2010) .
Bovine trachea strips were mounted with silk ties, whereas mouse trachea were mounted with triangular wires and incubated in water-jacketed 8 ml organ baths in PSS pre-gassed with 95% O 2 -5% CO 2 at 37°C. A resting force of 0.9-1.0 g was applied and tissue was allowed to equilibrate for at least 45 min followed by pre-contraction with alternating treatments of 75 mM KCl three times every 10 min to establish viability. At the end of the equilibration period, bovine and mouse trachea were stimulated with the muscarinic agonist, carbachol (Sigma, St Louis, MO, USA), at designated carbachol concentrations. Nerve-mediated smooth muscle contractions were also elicited by EFS using a pair of electrodes mounted in the tissue bath in parallel to the tracheal strips, similar to previous studies in this laboratory (Kamm & Stull, 1985b; Ding et al. 2009; Tsai et al. 2012) . Pulses of 0.5 ms in duration were delivered in trains at frequencies (1-80 Hz) by a DC power amplifier (HP 6824A; Hewlett-Packard, Palo Alto, CA, USA) driven by a Grass S88 stimulator (Grass Instrument Company, Quincy, MA, USA) at 20 V. Maximal responses were obtained at 30 Hz. After tracheal muscle strips were pretreated with cholinesterase inhibitor neostigmine (2 μM) or muscarinic antagonist atropine (1 μM) for 20 min, contractions were elicited at 30 Hz. Responses obtained at 30 Hz before application of inhibitors were used as a reference value for normalizing subsequent contractile responses. Force developments were recorded isometrically by a Grass FT03 force transducer connected to Powerlab 8/SP data acquisition unit (AD Instruments, Colorado Springs, CO, USA). Force measurements were normalized as grams of developed force per tissue wet weight for bovine trachea.
At the indicated times after specific treatments, tissues were quick frozen by clamps pre-chilled in liquid nitrogen and were processed as described previously (Gao et al. 2013) . Briefly, frozen tissues were stored at −80°C until added to a frozen slurry of acetone with 10% trichloroacetic acid and 10 mM DTT and then slowly thawed at room temperature. Tissues were rinsed with ether (three times for 10 min each), exposed to air for a few minutes for ether evaporation and suspended in urea sample buffer containing 8 M urea, 20 mM Tris (pH 8.6), 23 mM glycine, 10 mM DTT, 4 mM EDTA and 5% sucrose. Proteins were then solubilized in a Bullet Blender (Next Advance, Inc., Averill Park, NY, USA) with the addition of urea crystals to saturation (with 2 mm zirconium oxide beads, four spins of 3 min each at setting 9). Protein content was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA) with BSA as the standard. Bromophenol blue was added to 0.004% and samples were stored at −80°C.
Western blot analysis
Tissue extracts solubilized in urea sample buffer were added to 0.25 volumes of SDS sample buffer containing 250 mM Tris (pH 6.8), 10% SDS, 50 mM DTT, 40% glycerol and 0.01% bromophenol blue and were then boiled for SDS-PAGE (4-12% or 8-18% polyacrylamide gradient). Proteins were transferred onto a nitrocellulose membrane and visualized by immunoblot staining using antibodies to MYPT1 (mouse; BD Transduction Laboratories, Lexington, KY, USA), pan-MYPTs (rabbit; Masumi Eto, Thomas Jefferson University, Philadelphia, PA, USA), PP1cδ (rabbit; Millipore, Billerica, MA, USA), phospho-MLCK S1760 (rabbit; ProSci, Fort Collins, CO, USA), MLCK (mouse, K36; Sigma), ROCK1 (rabbit; BD Biosciences, San Jose, CA, USA), CPI-17 (rabbit; Santa Cruz Biotechnology, Santa Cruz, USA), phospho-MYPT1 T853 (rabbit; Upstate Biotechnology, Lake Placid, NY, USA), phospho-MYPT1 T696 (rabbit; Upstate Biotechnology), phospho-CPI-17 Thr38 (goat; Santa Cruz Biotechnology), phospho-paxillin Y118 (rabbit; Cell Signaling Technology, Beverly, MA, USA) and paxillin (mouse; BD Transduction Laboratories). The pan-MYPTs antibody was raised to the conserved sequence in human MYPT1 residues 674-684 that is identical with respect to MBS85 for human, mouse and bovine proteins (Grassie et al. 2011) . GAPDH was stained with anti-GAPDH antibody (rabbit; Santa Cruz Biotechnology) as a loading control. Total protein blots for MYPT1, PP1cδ, MBS85, ROCK1 and CPI-17 were expressed as ratios relative to the immunoblot of MLCK. We used MLCK to normalize to a protein in the contractile system. We have performed normalization to GAPDH and the values for mouse trachea are lower than other smooth muscles, presumably as a result of GAPDH from nonsmooth muscle cells. For the larger tissues, we are able to prepare smooth muscle strips that are ß90% smooth muscle cells, although this is more difficult for the mouse trachea because of the smaller amount of smooth muscle cells in the tissue. Similar to RLC, the MLCK content relative to GAPDH is twice as great in the bladder compared to other smooth muscles (Gao et al. 2013) . Total protein blots for PP1cδ and MBS85 were also expressed as ratios relative to MYPT1 total. The phosphorylation of MYPT1 (T853 or T696) was expressed as a ratio of phospho-MYPT1 to MYPT1 total and normalized with the average response values to calyculin A (LC Laboratories, Woburn, MA, USA). The phosphorylation of CPI-17 was obtained as a ratio of phosphorylated CPI-17 to CPI-17 total and normalized to the phosphorylation response to phorbol 12, 13-dibutyrate (Tsai et al. 2014) . The phosphorylation of paxillin was expressed as a ratio of phospho-paxillin to paxillin total. MLCK and MBS85 phosphorylation were normalized to the response obtained with calyculin A. Quantification of western blots was determined by quantitative densitometry using ImageQuantTL (Molecular Dynamics, Sunnyvale, CA, USA).
Measurement of myosin and MYPT1 content in different smooth muscles
Smooth muscle tissue proteins (10 μg) were separated by SDS-PAGE on 4-12% Bolt gradient gels in 1 × Mops running buffer (Invitrogen, Carlsbad, CA, USA) and then transferred to nitrocellulose membrane as described above. MYPT1 and MBS85 content in smooth muscles were measured by comparison with a standard curve of MYPT1 peptide (residues 654-880; Millipore) on the same membrane, using the pan-MYPTs antibody that was raised to residues 674-684 or another MYPT1 antibody that was raised to residues 661-710 (LS-C117671; LSBio, Seattle, WA, USA). Myosin heavy chain content in the same samples (1.5 μg) was measured by comparison with a standard curve of smooth muscle heavy meromyosin in a Coomassie-stained gel. The amount of total tissue proteins loaded for quantifications was pre-optimized for detection of signals in a linear range. When calculating concentrations of proteins in tissues (μM), it was assumed that 20% of tissue wet weight was protein and, based on density estimations, the calculated volume of 1 μg of total protein measured by the Bradford assay was 0.947 nl. Using these assumptions as established, the concentration of myosin was comparable to previously published values (Cohen & Murphy, 1978; Dimopoulos et al. 2007 ).
Measurement of RLC phosphorylation
RLC phosphorylation was measured by urea/glycerol-PAGE as described previously (Kamm et al. 1989; Gao et al. 2013) . Muscle proteins in 8 M urea sample buffer were subjected to urea/glycerol-PAGE to separate nonphosphorylated and monophosphorylated RLC (There were no significant amounts of diphosphorylated RLC). Following electrophoresis, proteins were transferred to nitrocellulose membranes and probed with mouse monoclonal antibodies against smooth muscle RLC. The ratio of monophosphorylated RLC to total RLC (nonphosphorylated plus monophosphorylated) was determined by quantitative densitometry. Under the conditions of the electrophoresis at alkaline pH, relative rates of migration (slow to fast) include nonphosphorylated RLC, monophosphorylated RLC and diphosphorylated RLC. Thus, we have a direct quantitative measure of the extent of RLC phosphorylation. Because the separation results from the charges on a single or double phosphate, data may be calculated as mol of phosphate/mol of RLC (Perrie et al. 1972) . As noted previously for isolated smooth muscles, the amount of diphosphorylation in response to agonist or EFS is generally negligible relative to the amount of monophosphorylated RLC, including bovine trachea. (Persechini et al. 1986; Miller-Hance et al. 1988; Isotani et al. 2004; He et al. 2008; Ding et al. 2009; Tsai et al. 2012; Gao et al. 2013) 
Histology and immunohistochemistry
The isolated trachea from MYPT1 SM+/+ or MYPT1 SM−/− mice were fixed in 4% (w/v) paraformaldehyde overnight, embedded in paraffin and transversely sectioned at a thickness of 6 μm. After dewaxing and hydration, the sections were stained with standard haematoxylin and eosin. For immunohistochemistry, fresh trachea sections were embedded with OCT and blocked with phosphate-buffered saline containing 0.1% Triton X-100, 0.1% Tween 20, 1% BSA and 5% non-immune goat serum for 1 h at room temperature, and then incubated with primary antibody: anti-MYPT1 (rabbit; BD Transduction Laboratories) or anti-smooth muscle α-actin (mouse; Sigma) overnight, and then incubated with secondary antibodies conjugated with either Alexa Flour 488 (Life Technologies, Gaithersburg, MD, USA) for smooth muscle α-actin or 569 (Life Technologies) for MYPT1. Microscopy was performed using an Eclipse 400 fluorescence microscope or a confocal microscope (Olympus, Tokyo, Japan).
Statistical analysis
All data are reported as the mean ± SEM. Statistical comparisons were performed using Student's t test for comparison between control and treatment groups. For multiple comparisons, one-way ANOVA followed by Dunnett's post hoc test or two-way ANOVA with Tukey's post hoc test was used. Data analyses were performed with Prism, version 6.0 (GraphPad Software, San Diego, CA, USA). P < 0.05 was considered statistically significant.
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Results
Regulatory protein contents related to RLC phosphorylation in different smooth muscle tissues
There are differences in the amounts of expression of MLCK, MLCP and CPI-17 in different smooth muscles tissues (Gong et al. 1992; Somlyo & Somlyo, 2003; Kitazawa & Kitazawa, 2012; Gao et al. 2013) , although little is known specifically about their expression in airway smooth muscles. Therefore, we compared the expression of different regulatory proteins in bladder, ileum and aorta with both bovine and mouse trachea (Fig. 1) . Western blots showed similar amounts of MLCK expression, although with a two-fold enrichment in mouse bladder smooth muscle, which is consistent with a previous study (Tsai et al. 2014) . Myosin heavy chain was also expressed in a two-fold greater amount in bladder smooth muscle compared to the other smooth muscles (Table 1) . Therefore, we normalized the expression of the other signalling proteins to the amount of MLCK for a relative comparison to contractile protein content (Fig. 1) . MYPT1 was expressed in all smooth muscle tissues, although both mouse and bovine tracheal smooth muscle had significantly smaller amounts (Fig. 1B and Table 1 ). Quantitative measures of MYPT1 showed an average intracellular concentration of ß1 μM for the different smooth muscle tissues, which was substantially less than the average myosin heavy chain concentration of 58 μM (Table 1) . Because MBS85 (member of the MYPT1 family) was significantly expressed in bladder (Tsai et al. 2014 ) and ileal ) smooth muscles, we measured its expression in airway smooth muscles. MBS85 contains the RVxF motif and a more N-terminal site with the consensus sequence RxxQV/I/LK/RxY/W that probably also serves as a scaffolding protein binding both PP1cδ and myosin (Terrak et al. 2004; Grassie et al. 2011) . MBS85 was expressed in the different smooth muscle tissues, with the largest amount in bovine tracheal smooth muscle ( Fig. 1B and C) . The pan-MYPT1 antibody raised to human residues 674-684 is identical in MBS85 for human, mouse and bovine proteins and so the relative differences are not explained by different immunoreactivities.
The amount of PP1cδ was greater in phasic smooth muscles, although differences between aorta and trachea were not marked. CPI-17 expression showed relative Bars represent the mean ± SEM (n ࣙ 5). * P < 0.05 and * * * P < 0.001 compared to bladder smooth muscle. C, MBS85 (top) and PP1cδ (bottom) amounts were normalized to MYPT1 content. Bars represent the mean ± SEM (n ࣙ 5). * * * P < 0.001 compared to bladder smooth muscle. Blad, bladder; mTrach, mouse trachea; bTrach, bovine trachea. Myosin heavy chain in different tissues, as well as bladder MYPT1 and MBS85, was measured quantitatively with standard purified protein, as described in the Methods section. MYPT1 and MBS contents in other tissues were calculated from the data shown in Fig. 1 , as also described in the Methods section. All tissues were from mice except for bovine trachea. Significance is shown compared to bladder content.
amounts for bladder > aorta > ileum >> mouse and bovine trachea. Although there are differences in the amounts of expression, the presence of these signalling proteins in tracheal smooth muscle could result in their contribution to the modulation of RLC phosphorylation.
When the amount of MBS85 expression was compared with MYPT1 expression, tracheal tissues showed a greater relative amount compared to bladder, ileum and aorta (Fig. 1C) . Similarly, there was a greater amount of PP1cδ relative to MYPT1 in trachea compared to the other smooth muscles, presumably as a result of its binding to both MYPT1 and MBS85.
Temporal responses to carbachol and KCl treatments in bovine tracheal smooth muscle
Representative protein and phosphoblots for RLC, MYPT1 T696, MYPT1 T853, MBS85, CPI-17, MLCK and paxillin with 10 μM carbachol and 75 mM KCl treatments show temporal phosphorylation responses ( Fig. 2A) . Quantitation of these results indicates greater RLC phosphorylation and force responses to carbachol compared to KCl for both initial and sustained responses (Fig. 2B) . Previously, it was shown that these responses were associated with greater [Ca 2+ ] i values for KCl compared to carbachol, thus demonstrating Ca 2+ sensitization in tracheal smooth muscle with agonist treatment (Tang et al. 1992) .
Phosphorylation responses for MYPT1, CPI-17, MLCK, MBS85 and paxillin to carbachol and KCl treatments were also measured (Fig. 2C ). There were marked and rapid increases in phosphorylation of MYPT1 T853, CPI-17, and MLCK with carbachol. KCl treatment elicited a smaller response for MYPT1 phosphorylation with no CPI-17 phosphorylation, whereas MLCK phosphorylation was the same as that found with carbachol treatment. Constitutive phosphorylation of MYPT1 T696 and the analogous site in MBS85 (T560) was similar and increased to a small extent with KCl treatment. There was a greater extent of MYPT1 T696 but not MBS85 phosphorylation with carbachol treatment. Paxillin phosphorylation was significantly slower than phosphorylation of the other proteins, with a greater response to carbachol compared to KCl treatments. Thus, agonist stimulation of muscarinic receptors in tracheal smooth muscle was associated with phosphorylation of different signalling proteins that could affect RLC phosphorylation and force development.
Sensitivities with respect to the agonist concentration for the phosphorylation of these different proteins were investigated (Fig. 3A) . Carbachol concentration was varied from 0.01 to 10 μM and temporal responses were measured up to 10 min. Force and RLC phosphorylation responses were similarly affected both in terms of sensitivity to carbachol and temporally, resulting in a proportional relationship between the two at different times (Fig. 3A) . The EC 50 values for force were similar with 0.29, 0.21 and 0.15 μM at 2, 5 and 10 min, respectively, with similar EC 50 values being obtained for RLC phosphorylation (data not shown). The results at 10 min for force and RLC phosphorylation are shown in Fig. 3B . By contrast, the EC 50 values for MLCK (0.04 μM) were lower. The EC 50 values for MYPT1 T696 and T853 phosphorylation were in the same range as the values for force and RLC phosphorylation (Fig. 3B) . However, CPI-17 phosphorylation was the least sensitive to carbachol (Fig. 3B) .
Smooth muscle contraction also requires the polymerization of submembranous cytoskeletal actin filaments to strengthen the membrane adhesion complexes involved in transmitting the force generated in actin-myosin filaments to extracellular structures (Gunst & Zhang, 2008) . Recent evidence shows that nonmuscle myosin II plays a critical role in airway smooth muscle contraction by regulating the assembly of membrane adhesome complexes mediating the cytoskeletal processes required for force generation 0.8 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (Tsai et al. 2014) . CPI-17 phosphorylation was normalized to that obtained with phorbol 12, 13-dibutyrate (PDBu) (Tsai et al. 2014) . Paxillin phosphorylation was normalized to the response obtained with carbachol (10 min). Data are the mean ± SEM from n ࣙ 10 tissues each. * P < 0.05, * * P < 0.01 and * * * P < 0.001 compared to KCl at same time.
Responses to KCl or carbachol were all significantly greater than the resting values (P < 0.01), except for CPI-17 response to KCl. The SEM bars may be smaller than the symbols for the means. (Zhang & Gunst, 2017) . Although paxillin at membrane adhesions undergoes tyrosine phosphorylation more slowly than RLC phosphorylation (Fig. 3) , its sensitivity to different concentrations of carbachol was similar to RLC phosphorylation and force development, with EC 50 values in the range from 0.32 to 0.24 μM at 5 and 10 min, respectively. In summary, there appeared to be tight coupling in the sensitivity to carbachol stimulation of muscarinic receptors for force development and phosphorylation of RLC, MYPT1 T696 and MYPT1 T853. The sensitivity of MLCK phosphorylation was greater, whereas the sensitivity of CPI-17 phosphorylation was lower. Agonist concentration-response measurements revealed different phosphorylation relationships compared to temporal responses obtained at one agonist concentration that elicited the maximal force development response.
Cholinergic neurostimulation of tracheal smooth muscle elicits different signalling responses compared to bath application of the cholinergic agonist carbachol
EFS of bovine tracheal smooth muscle resulted in rapid force development within 10 s that was inhibited with atropine, showing responses similar to those reported in previous studies (Fig. 4A) (Kamm & Stull, 1985b; . EFC also rapidly increased RLC phosphorylation (Fig. 4A) . EFS by itself did not increase MYPT1 T696, MYPT1 T853, MBS85 or paxillin phosphorylation, although it significantly increased CPI-17 and MLCK phosphorylation. These phosphorylation responses, as well as force development, were inhibited with the muscarinic antagonist atropine (Fig. 4) .
Pre-treatment of bovine tracheal tissues with the cholinesterase inhibitor neostigmine altered the responses Mean phosphorylation response to 0.01 μM was not different from the resting value and so it was normalized to 0 with the response to 10 μM carbachol as 1.00 for the different times. The SEM bars may be smaller than the symbols for the means (n ࣙ 10). * * * P < 0.001 compared to force value. 595.19 to EFS (Fig. 4) . RLC, MLCK and paxillin phosphorylation, as well as basal force, increased in the presence of neostigmine without EFS, presumably as a result of the effects of spontaneously released ACh. With EFS plus neostigmine, there was an enhancement of force development and phosphorylation of RLC, CPI-17, MLCK and paxillin. Neostigmine pre-treatment by itself did not significantly increase CPI-17, MYPT1 or MBS85 phosphorylation, although it did in combination with EFS. These results on MYPT1 696 and MYPT1 T853 phosphorylation with EFS in the presence of neostigmine are similar to those obtained with bath applied carbachol.
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Genetically modified mice provide insights into signalling to RLC phosphorylation in tracheal smooth muscle cells
Previous studies on MYPT1-deficient phasic smooth muscles reported modest changes in developed force and RLC phosphorylation in response to agonists Tsai et al. 2014) . However, tonic smooth muscles typically show robust Ca 2+ sensitization responses (Tang et al. 1992; Somlyo & Somlyo, 2003; Hartshorne et al. 2004; Dimopoulos et al. 2007) . Therefore, we investigated the effect of MYPT1-deficiency in mouse trachea. Results with trachea from adult mice with a conditional MYPT1 knockout showed no obvious histological changes in the smooth muscle layer compared to wild-type mice (Fig. 5A) . Immunostaining showed MYPT1 expression not only in the smooth muscle layer identified by α-smooth muscle actin staining, but also in nonsmooth muscle cells in the trachea from MYPT1 SM+/+ mice (Fig. 5B) . However, after tamoxifen treatment, MYPT1 immunostaining was reduced in the smooth muscle cells compared to the non-muscle cells in trachea from MYPT1 SM-/-mice. The residual immunostaining could be a result of residual MYPT1 in smooth muscle cells or cross-reactivity of antibody with MBS85. Therefore, the smooth muscle layer was dissected from trachea to analyse MYPT1 expression quantitatively by western blotting compared to other All EFS force responses in the presence or absence of neostigmine were greater than the value at 0 s ( * * * P < 0.001). Force was not increased with EFS in the presence of atropine. Neostigmine pre-treatment increased the value at 0 s ( * * * P < 0.001). B, phosphorylation of MYPT1 T853 (top), MYPT1 T696 (middle) and MBS85 (bottom) on the left and CPI-17 (top), MLCK (middle) and paxillin (bottom) on the right in response to EFS alone (open bars) or after pretreatment with 2 μM neostigmine (solid bars) or 1 μM atropine (grey bars). MYPT1 and MLCK phosphorylation values were normalized to the mean response obtained to calyculin A treatment, whereas CPI-17 phosphorylation was normalized to the mean response obtained with phorbol 12,13-dibutyrate (PDBu). The paxillin phosphorylation values were normalized to the mean response obtained with 10 μM carbachol at 10 min. Values are the mean ± SEM (n ࣙ 6). * * * P < 0.001 compared to values at 0 s. Comparisons were also made between EFS without and with neostigmine ( # P < 0.05; ### P < 0.001).
proteins (Fig. 5C ). MYPT1 was reduced to less than 10% in trachea from MYPT1 SM-/-mice compared to MYPT1 SM+/+ mice. Additionally, PP1cδ was also reduced in trachea from MYPT1 SM-/-mice, presumably as a result of the loss of MYPT1, which disrupts the formation of a stable protein complex between the two proteins. There were no changes in the expression of MBS85, CPI-17, RLC, MLCK or ROCK1 in MYPT1-deficient tracheal smooth muscle.
Additional studies were performed on the potential functional consequences of MYPT1 deficiency (Fig. 6A) . Force development and RLC phosphorylation responses to carbachol were no different for trachea from MYPT1-deficient mice compared to wild-type mice, including both maximal and sustained force responses, in contrast to phasic smooth muscles showing enhanced sustained contraction in jejunum , enhanced maximal force in bladder tissue (Tsai et al. 2014) and enhanced maximal and sustained force in mesenteric artery (Qiao et al. 2014) .
In the contractile studies, we also included trachea from MYPT1 T853A knock-in mutant mice where the T853 residue was made nonphosphorylatable by an alanine replacement. Contractile responses to carbachol showed no differences compared to trachea from both MYPT1 SM+/+ and MYPT1 SM-/− mice (Fig. 6A ). Concentration-force development relationships to carbachol were investigated because MYPT1-deficient mesenteric arteries had an increased sensitivity to the agonist norepinephrine in force development (Qiao et al. 2014) . Temporal measurements at different concentrations of carbachol showed similar responses
PP1Cδ * * * * * * GAPDH +/+ −/− CPI-17 (Fig. 6B) . Thus, MYPT1 deficiency or mutation of MYPT1 T853 to a nonphosphorylatable residue had no significant effect on the contractile responses of mouse trachea to carbachol.
Discussion
The general mechanism for RLC phosphorylation/ dephosphorylation and force development/relaxation in phasic and tonic smooth muscles involves MLCK and MLCP (Kamm & Stull, 1985a; Hartshorne, 1987; Hai & Murphy, 1989; Kamm & Stull, 2001; Somlyo & Somlyo, 2003; Kim et al. 2008; Puetz et al. 2009; Cole & Welsh, 2011) . However, the involved signalling modules affecting RLC phosphorylation have different properties in different smooth muscles.
Role of MYPT1 in RLC phosphorylation in smooth muscle cells
Our characterization of protein expression related to RLC phosphorylation in tracheal smooth muscle showed that CPI-17 and MYPT1 content was low compared to other kinds of smooth muscles. A surprising result was the relatively abundant expression of MBS85 in trachea compared to MYPT1 where it may also bind PP1cδ similar to MYPT1, serving as a similar scaffolding protein in myosin thick filaments (Grassie et al. 2011) . Although the amount of PP1cδ is reduced in MYPT1-deficient trachea (presumably as a result of degradation of free PP1cδ), the remaining PP1cδ bound to MBS85 may be sufficient to dephosphorylate RLC. Thus, MYPT1 and MBS85 may functionally share roles in MLCP so that residual PP1cδ bound to MBS85 may be sufficient to compensate for the loss of PP1cδ bound MYPT1. Quantitation shows the amount of both MYPT1and MBS85 in different smooth muscles is ß60-fold less than the amount of myosin heavy chain. Our direct measures of myosin heavy chain content in mouse smooth muscles are consistent with previously reported values in different porcine smooth muscles (Cohen & Murphy, 1978) . MYPT1 content was also similar to that measured in rabbit femoral artery (Dimopoulos et al. 2007 ) and estimated by purification from chick gizzard (Alessi et al. 1992) and pig bladder (Shirazi et al. 1994) . It is not yet clear how PP1cδ tightly bound to MYPT1 or MBS85 in myosin filaments dephosphorylates the substantially greater amount of phosphorylated RLC, particularly because significant extents of constitutive phosphorylation of MYPT1 and MBS85 are predicted to inhibit PP1cδ activity. For example, MLCK binds tightly to contractile proteins where its N-terminal tail binds tightly to actin filaments with displacement of the catalytic core towards myosin filaments (Lin et al. 1997; Hatch et al. 2001; Mabuchi et al. 2010) . MLCK contains a sufficiently extensible linker that enables it to remain bound to F-actin and simultaneously phosphorylate RLC in the myosin heads of adjacent myosin filaments. Another possibility is that a soluble form of PP1cδ may also dephosphorylate RLC (Tsai et al. 2014) .
In summary, MLCP may consist of multiple molecular forms so that the knockout of MYPT1 in tracheal and other smooth muscles has modest effects on smooth muscle contraction, in contrast to results for the respective knockout of MLCK (He et al. 2008; Wang et al. 2010; Zhang et al. 2010; He et al. 2011; Gao et al. 2013) or myosin (Morano et al. 2000; Lofgren et al. 2003 ) that leads to smooth muscle failure and death in mice.
Role of MYPT1 T853 phosphorylation in smooth muscle contraction
Overexpression of both MYPT1 and PP1cδ in mammalian cells provided recombinant MLCP that retained biochemical enzymatic properties of the native enzyme in contrast to reconstituted, bacterially expressed proteins (Khasnis et al. 2014) . Selective thiophosphorylation of the mammalian MYPT1 at Thr696 with ROCK inhibited MLCP activity, whereas the Thr853 thiophosphorylation did not alter the phosphatase activity. Constitutive phosphorylation of MYPT1 T853 is typically lower than constitutive phosphorylation of MYPT1 T696. Increased MYPT1 T853 phosphorylation with agonist treatment in smooth muscles is inhibited with chemical inhibitors of ROCK (Somlyo & Somlyo, 2003; Eto & Kitazawa, 2017) . It was proposed that MYPT1 T853 phosphorylation was a marker for ROCK activity in smooth muscles (Eto & Kitazawa, 2017) . ROCK inhibitors also inhibit phosphorylation of other proteins that may affect contractile responses. For example, inhibition of ROCK reduced cofilin phosphorylation associated with a decline in G-actin and blocked the myogenic response (Moreno-Dominguez et al. 2013) . Although pharmacological approaches provide useful insights, their selective effects on multifunctional protein kinases, as well potential nonselective effects on other cellular processes, emphasize the need for corroborative experimental approaches.
Our genetic investigations with mice have provided insight into the function of the two MYPT1 phosphorylation sites. With the knock-in mutation MYPT1 T696A, the tonic component of force development and RLC phosphorylation was reduced in bladder smooth muscle, suggesting that loss of the constitutive phosphorylation of MYPT1 T696 with its autoinhibitory effect increased MLCP activity. The knock-in mutation MYPT1 T853A did not significantly change agonist-induced RLC phosphorylation and force development in the phasic bladder and ileum smooth muscles (Qiao et al. 2014; Gao et al. 2016) . In the present study, we report a similar result for tonic airway smooth muscles. Thus, although MYPT1 T853 phosphorylation increases in response to ROCK activation, it does not appear to play a role in modulating RLC phosphorylation and force development in different kinds of smooth muscles, consistent with biochemical observations (Eto & Kitazawa, 2017) .
Cholinergic neurotransmission signalling to RLC phosphorylation in smooth muscle MYPT1 phosphorylation was less sensitive to carbachol than CPI-17 and RLC phosphorylation in urinary bladder smooth muscle (Mizuno et al. 2008) . Surprisingly, this appears to be the only study involving agonist concentration/phosphorylation responses for MYPT1 and CPI-17 in smooth muscle tissues. In tracheal smooth muscle, RLC and MYPT1 phosphorylation had similar carbachol concentration-dependencies, with CPI-17 being less sensitive and MLCK being more sensitive. Differences in sensitivity to agonist concentration indicates signalling pathways may be recruited differently to affect RLC phosphorylation.
Studies using EFS to initiate cholinergic neurotransmission in isolated mouse bladder smooth muscle tissues reported that the phosphorylation of constitutively phosphorylated MYPT1 was not increased in contrast to cholinergic agonist treatment (Ding et al. 2009; Tsai et al. 2012) . Similar results were subsequently reported for gastric fundus (Bhetwal et al. 2013) where the data suggested that the accessibility of nerve-released ACh may be limited to a restricted population of receptors, possibly expressed by ICC-IMs. Thus, ACh from neurones does not appear to be linked to ROCK activation and MYPT1 phosphorylation. These results may be a J Physiol 595.19 result of the unique anatomical organization of the neuroeffector junction in gastrointestinal smooth muscles, which involves information transfer between motor neurons, ICC-IMs and smooth muscle cells. We obtained supportive results with EFS in another gastrointestinal tissue: the ileum . Although urinary bladder smooth muscle tissues contain ICC cells, they are not as abundant as in the gastrointestinal system (McCloskey et al. 2009; McCloskey, 2011; Yu et al. 2012) . Unlike ICCs in gut, it is not apparent that they have any function in normal bladder contraction. Airway smooth muscles do not contain ICCs. The lack of MYPT1 phosphorylation in response to EFS in bladder and tracheal smooth muscle suggests an alternative mechanism not involving ICCs.
Other potential mechanisms for the differences in pharmacological vs. EFS responses and effects on the ROCK pathway to MYPT1 phosphorylation include (i) differences in the effects of carbachol vs. ACh; (ii) muscarinic receptor subtypes activated by neural and cholinergic stimulation; or (iii) differences in activation of different networks with G protein-coupled receptors. At concentrations that elicit maximal responses, we obtain similar results for the phosphorylation of smooth muscle signalling proteins with carbachol or ACh (He et al. 2011; He et al. 2013; Tsai et al. 2014; Chen et al. 2015) . The EFS was performed at a frequency that elicited similar maximal force and RLC phosphorylation responses. Although trachea and other smooth muscles express M2 and M3 receptors, smooth muscle contraction of the airways occurs largely, if not exclusively, via M3 receptors (Michel & Parra, 2008) . Thus, differences in the chemical effector or muscarinic receptors do not provide a satisfactory explanation.
Another potential mechanism may involve differences in G protein networks coupled to M3 muscarinic receptors (Artamonov et al. 2013) . Parasympathetic cholinergic neurotransmission in airways involves the release of ACh from nerve endings triggered by a propagated action potential that is mimicked by EFS (Racke & Matthiesen, 2004) . ACh action is terminated by acetylcholinesterase, which is highly expressed around cholinergic nerves. ACh binds to muscarinic receptors where Gq/G11 links these receptors to the rapid activation of phospholipase C, leading to the formation of inositol-1,4,5-trisphosphate and the release of intracellularly stored Ca 2+ . [Ca 2+ ] i is also derived to a considerable extent from a transmembrane influx through particular cation channels, such as voltage-dependent L-type Ca 2+ channels and transient receptor potential channels (Mironneau & Macrez-Lepretre, 1995; Somlyo & Somlyo, 2003; Althoff & Offermanns, 2015) . EFS of smooth muscle, including airway smooth muscle, initiates a rapid increase in [Ca 2+ ] i , with further increases tightly coupled to MLCK activation and RLC phosphorylation (Kamm & Stull, 1985b; Miller-Hance et al. 1988; Tang et al. 1992; Ding et al. 2009 ).
The G proteins G12/G13 link receptors to the Rho/Rho-kinase pathway via activation of particular Rho guanine nucleotide exchange factors (RhoGEFs), including PDZ-RhoGEF and leukaemia-associated RhoGEF, which then promote the formation of active RhoA that activates ROCK. The activation of RhoGEFs lag significantly between the initial increase in [Ca 2+ ] i and force (ms) to the onset of Ca 2+ -sensitized force development (s) (Artamonov et al. 2013) . Thus, a single electrical stimulus may provide sufficient muscarinic receptor activation for the Gq/11 pathway followed by the rapid ACh hydrolysis by acetylcholinesterase. However, the slower G12/G13 may not be activated before ACh is hydrolysed. Bursts of ACh release and rapid hydrolysis between each EFS stimulus could still result in activation of MLCK similar to that reported for the frequency-dependent activation of MLCK in skeletal muscle (Ryder et al. 2007; Stull et al. 2011) . The activation of the G12/13 and Rho/Rho-kinase pathway for MYPT1 phosphorylation may require a more prolonged activation of the muscarinic receptor such as that found with EFS in the presence of neostigmine or the bath applied agonist carbachol. This hypothesis involving degenerate G protein network signalling provides a potential mechanism not requiring ICCs, although this needs to be investigated experimentally in intact smooth muscle cells (Artamonov et al. 2013) .
In summary, MYPT1 may functionally share a role in MLCP activity with MBS85, as well as a soluble PP1cδ, so that the knockdown of MYPT1 has minimal effects on RLC phosphorylation in smooth muscles. There are distinct responses in signalling modules acting on RLC phosphorylation and force development in response to pharmacological agonists compared to cholinergic neurostimulation in tonic tracheal smooth muscle similar to phasic smooth muscles. These distinct responses may be related to different temporal responsiveness of G protein networks.
